Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including other brain neurons; strongest in podocytes | 0.75 |
| chemistry Open Targets | compounds already reach it: elinzanetant, talnetant, fezolinetant +1 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 4 Parkinson's papers of 158 | 0.79 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 8534
Sealed predictions
- TACR3 in dopamine neurons, braak+0.78 (p 0.013) → +0.29 (p 0.443)receipt 8539
Swarm cases
receipt 8539: TACR3 in dopamine neurons, braak
- power
- full sample +0.60 (p 0.0086, n 18), 95% CI +0.18 to +0.83. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.61 (p 0.0069, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.60 (p 0.0089, n 18). not the mix.
- skeptic
- leave-one-out range +0.54 to +0.74, sign flips 0; without severely affected donors +0.60 (p 0.0086, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TACR3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts